{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:38:13Z","timestamp":1793968693428,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Diagnostica Brasil","award":["PMR-HPV"],"award-info":[{"award-number":["PMR-HPV"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The causal relationship between high-risk (hr) HPV infection and precancerous lesions or cervical cancer has led to the development of strategies to increase screening performance and prevent this cancer. The increased sensitivity of DNA-HPV testing compared to cervical cytology favors DNA-HPV testing as a primary screening test. Cervical cancer screening in Brazil is opportunistic, and this cancer remains a considerable health problem with a high proportion of diagnoses in advanced stages. This paper aims to describe the design and implementation of the Cervical Cancer Screening Program with primary DNA-HPV testing (CCSP-HPV) planned for Indaiatuba City (SP), Brazil; the strategies to achieve higher population coverage; and a study protocol for cost-effectiveness analyses.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The CCSP-HPV was designed based on successful guidelines that replaced cervical cytology-based screening by the DNA-HPV test performed at 5-year intervals. The screening will be performed for the female population aged 25-64\u2009years cared for by the public health system and aim to reach 80% coverage after completing the first round. The chosen DNA-HPV test detects 14 hr-HPV types and genotypes HPV-16 and 18. All women with a negative test will be reassessed after five years. Women showing a positive test for HPV-16 and\/or 18 will be referred for colposcopy. Those showing the other 12 hr-HPV types will be tested by cytology, and if any abnormality is detected, they will also be referred for colposcopy. The histopathologic evaluation will be reviewed by a pathologist panel and aided by p16 immunohistochemistry. A cost-effectiveness analysis will be performed by a Markov model comparing the cost of the new program and the screening performed by conventional cytology five years prior (2011\u20132016).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The new screening program is considered a breakthrough for public health regarding cervical cancer, which is the third leading cause of cancer death among Brazilian women. Achieving at least 80% coverage will have the possibility to change this scenario. The proposed program will provide a modern cervical cancer screening method for women, and information about cost-effectiveness will help other similar places support the decision of implementing cervical cancer screening using the DNA-HPV test.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-08688-4","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T16:33:42Z","timestamp":1588091622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol"],"prefix":"10.1186","volume":"20","author":[{"given":"Julio Cesar","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diama Bhadra","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Froes","family":"Bragan\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cirbia Silva","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Garcia","family":"Discacciati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Carlos","family":"Zeferino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"issue":"6","key":"8688_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"8688_CR2","unstructured":"BRASIL, Minist\u00e9rio da Sa\u00fade, Instituto Nacional do C\u00e2ncer-INCA. In: N\u00fameros do C\u00e2ncer. 2019. https:\/\/www.inca.gov.br\/numeros-de-cancer. Acessed 25 Nov 19."},{"issue":"2","key":"8688_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bpobgyn.2011.08.001","volume":"26","author":"L Denny","year":"2012","unstructured":"Denny L. Cytological screening for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):189\u201396.","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"issue":"2","key":"8688_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bpobgyn.2011.11.004","volume":"26","author":"TC Wright Jr","year":"2012","unstructured":"Wright TC Jr, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):197\u2013208.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"8688_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jama.283.1.87","volume":"283","author":"M Schiffman","year":"2000","unstructured":"Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87\u201393.","journal-title":"JAMA."},{"key":"8688_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jnci\/95.1.46","volume":"95","author":"ME Sherman","year":"2003","unstructured":"Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46\u201352.","journal-title":"J Natl Cancer Inst"},{"key":"8688_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","volume":"11","author":"G Ronco","year":"2010","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249\u201357.","journal-title":"Lancet Oncol"},{"key":"8688_CR8","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","volume":"370","author":"NW Bulkmans","year":"2007","unstructured":"Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764\u201372.","journal-title":"Lancet."},{"issue":"2","key":"8688_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","volume":"136","author":"TC Wright","year":"2015","unstructured":"Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189\u201397.","journal-title":"Gynecol Oncol"},{"issue":"9916","key":"8688_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials: international HPV screening working group. Lancet. 2014;383(9916):524\u201332.","journal-title":"Lancet."},{"issue":"3","key":"8688_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ajog.2012.11.020","volume":"208","author":"JT Cox","year":"2013","unstructured":"Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J, Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16\/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184 e1\u2013184.e11.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"8688_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/jnci\/dji162","volume":"97","author":"JJ Kim","year":"2005","unstructured":"Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97(12):888\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"8688_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1471-0528.2011.03228.x","volume":"119","author":"J van Rosmalen","year":"2012","unstructured":"van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG. 2012;119(6):699\u2013709.","journal-title":"BJOG."},{"issue":"1","key":"8688_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/GCO.0b013e32835c5d10","volume":"25","author":"J Dillner","year":"2013","unstructured":"Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol. 2013;25(1):11\u20136.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"8688_CR15","unstructured":"U.S. Food and Drug Administration, Premarket Approval (PMA). In: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P100020 Accessed 25 NOV 2019."},{"issue":"2","key":"8688_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178\u201382.","journal-title":"Gynecol Oncol"},{"key":"8688_CR17","unstructured":"Australian Government. Department of Health. National Cervical Screening Program. In: http:\/\/www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/cervical-screening-1. Accessed 25 Nov 2019."},{"key":"8688_CR18","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade, Instituto Nacional do C\u00e2ncer- INCA. Available in: https:\/\/www.inca.gov.br\/numeros-de-cancer. Accessed in: November 25th, 2019."},{"key":"8688_CR19","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de Aten\u00e7\u00e3o B\u00e1sica. Controle dos c\u00e2nceres do colo do \u00fatero e da mama. \u2013 2. ed. \u2013 Bras\u00edlia. Editora do Minist\u00e9rio da Sa\u00fade, 2013. In: Cadernos de Aten\u00e7\u00e3o B\u00e1sica, n. 13. http:\/\/189.28.128.100\/dab\/docs\/portaldab\/publicacoes\/cab13.pdf. Accessed 25 November 2019."},{"issue":"1","key":"8688_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1186\/s12889-019-7846-2","volume":"19","author":"DB Vale","year":"2019","unstructured":"Vale DB, Menin TL, Bragan\u00e7a JF, Teixeira JC, Cavalcante LA, Zeferino LC. Estimating the public health impact of a national guideline on cervical cancer screening: an audit study of a program in Campinas, Brazil. BMC Public Health. 2019;19(1):1492.","journal-title":"BMC Public Health"},{"issue":"6","key":"8688_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1055\/s-0038-1660841","volume":"40","author":"JC Teixeira","year":"2018","unstructured":"Teixeira JC, Maestri CA, Machado HDC, Zeferino LC, Carvalho NS. Cervical Cancer registered in two developed regions from Brazil: upper limit of reachable results from opportunistic screening. Rev Bras Ginecol Obstet. 2018;40(6):347\u201353.","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"8688_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/01443615.2018.1463976","volume":"39","author":"DB Vale","year":"2019","unstructured":"Vale DB, Sauvaget C, Muwonge R, Thuler LCS, Basu P, Zeferino LC, Sankaranarayanan R. Level of human development is associated with cervical cancer stage at diagnosis. J Obstet Gynaecol. 2019;39(1):86\u201390. https:\/\/doi.org\/10.1080\/01443615.2018.1463976 Epub 2018 Sep 19.","journal-title":"J Obstet Gynaecol"},{"key":"8688_CR23","unstructured":"Atlas of Human Development in Brasil, Indaiatuba, SP. The Municipal Human Development Index (MHDI). In: http:\/\/www.atlasbrasil.org.br\/2013\/en\/perfil_m\/indaiatuba_sp. Accessed 25 November 2019."},{"key":"8688_CR24","unstructured":"Seade Foundation, Porta de Estat\u00edsticas do Estado de Sao Paulo. Filtered by city \u201cIndaiatuba\u201d, the year \u201c2014\u201d, population \u201cwomen\u201d, and age group \u201c25 to 64 year\u201d. In: http:\/\/produtos.seade.gov.br\/produtos\/projpop\/index.php. Accessed 25 Nov 2019."},{"issue":"11","key":"8688_CR25","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Retrospective international survey and HPV time trends study group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol."},{"issue":"14","key":"8688_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnci\/dji187","volume":"97","author":"MJ Khan","year":"2005","unstructured":"Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"8688_CR27","unstructured":"International Federation of Cervical Pathology and Colposcopy (IFCPC). In: Terminologia colposcopica do colo uterino. http:\/\/www.ifcpc.org\/images\/docs\/nomenportug.pdf. Accessed 12 Feb 2015."},{"key":"8688_CR28","unstructured":"Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Coordena\u00e7\u00e3o de Preven\u00e7\u00e3o e Vigil\u00e2ncia. Divis\u00e3o de Detec\u00e7\u00e3o Precoce e Apoio \u00e0 Organiza\u00e7\u00e3o de Rede. Diretrizes brasileiras para o rastreamento do c\u00e2ncer do colo do \u00fatero. In: http:\/\/www.citologiaclinica.org.br\/site\/pdf\/documentos\/diretrizes-para-o-rastreamento-do-cancer-do-colo-do-utero_2016.pdf. Accessed 05 December 2019."},{"key":"8688_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-85014-1","volume-title":"Histological typing of female genital tract tumours [World Health Organization. International histological classification of Tumours]. 2nd ed","author":"RE Scully","year":"1994","unstructured":"Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours [World Health Organization. International histological classification of Tumours]. 2nd ed. Berlin: Springer-Verlag; 1994."},{"issue":"23","key":"8688_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18230","volume":"18","author":"H Kitchener","year":"2014","unstructured":"Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18(23):1\u2013196.","journal-title":"Health Technol Assess"},{"key":"8688_CR31","unstructured":"Health Council of the Netherlands. Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011; publication no. 2011\/07. In: https:\/\/www.rivm.nl\/en\/health-council-of-netherlands-population-screening-for-cervical-cancer. Accessed 22 Feb 2015."},{"key":"8688_CR32","unstructured":"Arbyn M, Haelens A, Desomer A, Verdoodt F, Thiry N, Francart J, et al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2015. KCE Reports 238. D\/2015\/10.273\/17. In: https:\/\/kce.fgov.be\/en\/cervical-cancer-screening-program-and-human-papillomavirus-hpv-testing-part-ii-update-on-hpv-primary. Accessed 22 Feb 2015."},{"issue":"9","key":"8688_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002388","volume":"14","author":"K Canfell","year":"2017","unstructured":"Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388.","journal-title":"PLoS Med"},{"issue":"5","key":"8688_CR34","first-page":"479","volume":"29","author":"RA Freitas","year":"2008","unstructured":"Freitas RA, Carvasan GA, Morais SS, Zeferino LC. Excessive pap smears due to opportunistic cervical cancer screening. Eur J Gynaecol Oncol. 2008;29(5):479\u201382.","journal-title":"Eur J Gynaecol Oncol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-08688-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T23:24:45Z","timestamp":1619565885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-08688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8688"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-08688-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In 2017, a law in the city of Indaiatuba that replaces conventional cytology by the DNA-HPV test for cervical cancer screening was approved. CCSP-HPV has become a standard of care. The UNICAMP Ethics Committee approved the study protocol (number 1,045,580, May 1, 2015) to evaluate the implementation and cost-effectiveness of CCSP-HPV. The Ethics Committee also approved the waiver of the Informed Consent Form, considering that this study will analyze data from health system records, without direct contact with patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Roche Diagnostics reviewed the study protocol before deciding to participate and to provide financial support for some activities of this study, including its HPV test chosen for the screening program. The authors have no other competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"576"}}